Postpartum haemorrhage (PPH) remains the major cause of maternal mortality in France. The
most efficient treatment of severe PPH is sulprostone which is associated with cardiac
complications. The objective of this study was to assess the efficacy and the safety of
intrarectal misoprostol for curative postpartum haemorrhage treatment.
We conducted a multicenter double blind randomized placebo control trial between June 2004
and December 2007, among consenting women with postpartum haemorrhage and failure to oxytocin
treatment.
Our main criteria of judgement was quantification of blood loss and the use of sulprostone
between the two groups using either misoprostol intrarectal tablets (5X200mg ) or placebo in
similar opaque introducer.